Compounds > 1,4,7,10-tetraazacyclododecane-1,7-diacetic acid
Page last updated: 2024-12-08
1,4,7,10-tetraazacyclododecane-1,7-diacetic acid
Description
1,4,7,10-tetraazacyclododecane-1,7-diacetic acid, often abbreviated as **DOTA**, is a **macrocyclic chelating agent**. This means it has a large ring structure containing multiple nitrogen atoms capable of binding metal ions.
Here's a breakdown of why DOTA is important for research:
**1. Metal Ion Coordination:**
* DOTA forms very stable complexes with a wide range of metal ions, including gadolinium(III), copper(II), and technetium(I). These complexes are extremely stable, meaning the metal ion is tightly bound and unlikely to dissociate.
**2. Applications in Medicine:**
* **Magnetic Resonance Imaging (MRI):** DOTA is used to create **contrast agents** for MRI. When complexed with gadolinium(III), it forms a compound called **gadolinium DOTA** (Gd-DOTA) which enhances the contrast in MRI images, allowing for better visualization of tissues and organs.
* **Radiopharmaceuticals:** DOTA complexes with radioactive metals like technetium(I) are used in **radiopharmaceutical imaging**. These complexes can target specific organs or tissues in the body, allowing for the detection and diagnosis of diseases.
* **Drug Delivery:** DOTA can be conjugated to drugs or other molecules, allowing for the development of targeted drug delivery systems. This can improve drug efficacy and reduce side effects.
* **Bio-conjugation:** DOTA can be used to attach metal ions to biomolecules like proteins and antibodies, facilitating their detection and manipulation.
**3. Research Uses:**
* **Metal Ion Sensing:** DOTA can be used as a sensor for specific metal ions. When a target metal ion binds to DOTA, it can induce a change in the molecule's fluorescence or other properties, allowing for its detection.
* **Catalysis:** DOTA complexes with metal ions can act as catalysts for various chemical reactions.
* **Material Science:** DOTA can be used to create functional materials with specific properties.
**In summary:** 1,4,7,10-tetraazacyclododecane-1,7-diacetic acid (DOTA) is a versatile and important molecule due to its ability to form stable complexes with metal ions. This property makes it a key component in various applications, ranging from medical imaging to catalysis, and fuels ongoing research in diverse fields.
1,4,7,10-tetraazacyclododecane-1,7-diacetic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 387353 |
CHEMBL ID | 1907387 |
SCHEMBL ID | 337070 |
MeSH ID | M0561373 |
Synonyms (10)
Synonym |
NCI60_028931 |
1,4,7,10-tetraazacyclododecane-1,7-diacetic acid |
2-[7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid |
SCHEMBL337070 |
SPSJFVXUOKRIGT-UHFFFAOYSA-N , |
CHEMBL1907387 |
112193-75-6 |
2,2'-(1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetic acid |
2-[7-(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetic acid |
R6KN864Z5Q |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.56 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.51 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |